The Right Medication to the Right Patient
A team of former senior directors from big pharma with combined 60+ years and more than 60 projects in diagnostics and 505(b)(2) drug development have secured exclusive worldwide rights to two high value assets, made available by a recent well-publicized R&D restructuring and divestment.
Escitalopram LAI (Long Acting Injectable)
An early stage asset at formulation stage. With the discovery and patenting of a novel salt to Escitalopram we can bring the first SSRI depot to the market.
First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025
505(b)(2) truncated development with LOE Q4 2038. Opportunity to out-license end of phase I
Estimated potential peak sales of over $1.5Bn (US and EU big 5)
CGRP mAb Diagnostic
Teva, in conjunction with Professor Rami Burstein from Harvard, discovered and patented a novel method of identifying the 50% of migraine patients who will respond to the CGRP class of drugs. This late stage asset can be brought to the market with a single clinical trial and generate a royalty stream to fund additional projects.
Diagnostic will offer best in class differentiation in a market expected to be worth $7Bn in 2025
Increased market share in a highly competitive market (Amgen/Novartis, Lilly, Lundbeck & Teva)
LOE patent extension of up to seven years on multibillion-dollar sales
We are in diligence on two additional projects that are complementary to our portfolio.
Why 428 Pharma?
Experienced pharma team with over 60 projects between the team in the area of diagnostics and 505(b)(2) drug development
Two projects gives a diverse and de-risked pipeline. Rapid time to market and revenue stream to fund additional projects